[HTML][HTML] Human papillomavirus vaccine efficacy and effectiveness against cancer
S Kamolratanakul, P Pitisuttithum - Vaccines, 2021 - mdpi.com
Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …
Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta …
Objective To explore the efficacy of human papillomavirus (HPV) vaccination on the risk of
HPV infection and recurrent diseases related to HPV infection in individuals undergoing …
HPV infection and recurrent diseases related to HPV infection in individuals undergoing …
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 …
SE Goldstone, AR Giuliano, JM Palefsky… - The Lancet Infectious …, 2022 - thelancet.com
Background The quadrivalent human papillomavirus (HPV) vaccine was shown to prevent
infections and lesions related to HPV6, 11, 16, and 18 in a randomised, placebo-controlled …
infections and lesions related to HPV6, 11, 16, and 18 in a randomised, placebo-controlled …
[HTML][HTML] The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease
AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …
SPERANZA project: HPV vaccination after treatment for CIN2+
A Ghelardi, F Parazzini, F Martella, A Pieralli, P Bay… - Gynecologic …, 2018 - Elsevier
Results From January 2013, all women diagnosed with a CIN2+ cervical lesion/stage IA1
cervical cancer treated with cervical conization in the Department of Obstetrics and …
cervical cancer treated with cervical conization in the Department of Obstetrics and …
[HTML][HTML] Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer
M Reuschenbach, J Doorbar, M Del Pino, EA Joura… - Vaccine, 2023 - Elsevier
Individuals with human papillomavirus (HPV)-related disease remain at risk for subsequent
HPV infection and related disease after treatment of specific lesions. Prophylactic HPV …
HPV infection and related disease after treatment of specific lesions. Prophylactic HPV …
[HTML][HTML] Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review
T Harder, O Wichmann, SJ Klug, MAB van der Sande… - BMC medicine, 2018 - Springer
Background Human papillomavirus (HPV) vaccination is safe and effective in preventing
cervical cancer in females. As HPV infections can also induce cancers of the anus, penis …
cervical cancer in females. As HPV infections can also induce cancers of the anus, penis …
Human papillomavirus–associated oropharyngeal cancer: review of current evidence and management
EL You, M Henry, AG Zeitouni - Current Oncology, 2019 - mdpi.com
Oropharyngeal cancer (OPC) has become the leading site for human papillomavirus (HPV)–
associated cancers in humans. It is an epidemic that remains relatively unfamiliar to most …
associated cancers in humans. It is an epidemic that remains relatively unfamiliar to most …
Present status of human papillomavirus vaccine development and implementation
R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …
A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older …
TJ Wilkin, H Chen, MS Cespedes… - Clinical Infectious …, 2018 - academic.oup.com
Background Adults living with human immunodeficiency virus (HIV) are at increased risk for
anal and oropharyngeal cancer caused by human papillomavirus (HPV). The efficacy of …
anal and oropharyngeal cancer caused by human papillomavirus (HPV). The efficacy of …